All In Biotech

Drug Trial Radar · NCT05877430

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Phase 1/2 Open Label, Safety and Preliminary Efficacy Study of a Live Biotherapeutic Product (CJRB-101) in Combination With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer

Last checked: Nov 19, 2026Latest source record: Dec 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Sep 11, 2023

Primary completion

Jul 2026

Study completion Oct 2027

Sponsor

Lead sponsor
CJ Bioscience, Inc.Industry
Sponsor type
Industry
First posted
May 26, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study CJB-101-01 will be conducted at multiple centers in the USA and Republic of Korea as an open-label safety and preliminary efficacy study of CJRB-101 in combination with pembrolizumab in subjects with selected types of advanced or metastatic cancer. The proposed study intends to address the unmet medical needs of low response rate and refractoriness to immune checkpoint inhibitors typically observed in this subject population by performing assessments of response, dose limiting toxicities, pharmacodynamic, and the effect on microbiome biomarkers at different dose levels of CJRB-101 combined with pembrolizumab.

Conditions

  • NSCLC
  • HNSCC
  • Melanoma
  • Metastatic Cancer
  • Advanced Solid Tumor
  • Advanced Cancer

Interventions

  • CJRB-101Drug

    In Phase 1, one or two capsules of CJRB-101 will be given every day. In Phase 2, the CJRB-101 dose selected from Phase 1 will be given every day.

  • Pembrolizumab injectionDrug

    200 mg given by intravenous (IV) infusion once every 3 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Phase 1&2] Tolerability and Safety: Incidence of Adverse EventsTime frame: Maximum 2 years
  2. [Phase 2] EfficacyTime frame: Maximum 2 years

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California, Irvine

    Irvine, California · Recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Samsung Medical Center

    Seoul, South Korea · Recruiting

  • Severance Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.